Daily non-political popular news in brief.
Risk and outcome similar for bypass surgery, drug-eluting stents
04-19-2007 · EurekAlert!Drug-eluting stent therapy and bypass surgery for coronary artery disease have about the same risk for a major cardiac event within 30 days after the procedures, researchers reported at the American Heart Association's 8th annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology.
Read more »
Keywords: risk, outcome, similar, bypass, surgery, drug-eluting, stents, drug, eluting, stent
« Previous | Next »
Similar news on "Risk and outcome similar for bypass surgery, drug-eluting stents":
- Second-generation drug-eluting stent system challenges current gold standard
03-24-2007 · EurekAlert!
While research shows that drug-eluting stents effectively reduce restenosis and revascularization compared to bare-metal stents, questions surrounding the safety of drug-eluting stents continue to dominate headlines. A study presented today at the American College of Cardiology’s Innovation in Intervention: i2 Summit surveys the safety and efficacy of the second generation Xience Everolimus Eluting Coronary Stent System (EES), compared to the current gold standard paclitaxel-eluting stent (PES), to determine if it offers similar or enhanced outcomes.
Similar news · Read more »
- Patients who receive drug-eluting stents should continue antiplatelet medications
01-16-2007 · EurekAlert!
Patients who have had drug-eluting stents inserted to prop open blocked coronary arteries should continue to take medications to reduce the risk of blood clots for at least one year after the stent is inserted, a new scientific advisory recommends.
Similar news · Read more »
- SCAI issues clinical alert on drug-eluting stents and late thrombosis
01-11-2007 · EurekAlert!
The Society for Cardiovascular Angiography and Interventions (SCAI) today released a clinical alert advising physicians on practical steps for reducing the risk of a rare but serious complication associated with drug-eluting stents. The document follows hearings held by the FDA's Circulatory Systems Device Panel. SCAI's clinical alert focuses on careful patient selection, meticulous stent implantation, and consistent use of medications to prevent the delayed formation of blood clots that can block blood flow to the heart.
Similar news · Read more »
- Second generation drug-eluting stent system challenges current gold standard
03-24-2007 · EurekAlert!
While research shows that drug-eluting stents effectively reduce restenosis and revascularization compared to bare-metal stents, questions surrounding the safety of drug-eluting stents continue to dominate headlines. A study presented today at the American College of Cardiology’s Innovation in Intervention: i2 Summit surveys the safety and efficacy of the second generation Xience Everolimus Eluting Coronary Stent System (EES), compared to the current gold standard paclitaxel-eluting stent (PES), to determine if it offers similar or enhanced outcomes.
Similar news · Read more »
- Jefferson scientists find that drug-eluting stents are disappointing in bypass grafts -- sometimes
03-26-2007 · EurekAlert!
While drug-eluting stents are effective in keeping open bypassed heart veins that aren’t too diffuse (filled with cholesterol plaque), a new study by cardiologists at Jefferson Medical College shows that they fare less well in keeping open bypassed veins with longer blockages. The researchers suggest that doctors think twice before inserting the drug-coated stents in such extensively diseased bypassed grafts.
Similar news · Read more »
- Bioabsorbable stent shows excellent performance
03-24-2007 · EurekAlert!
The use of slow-release drugs in stents (drug-eluting stents) has dramatically reduced restenosis rates after percutaneous coronary intervention. However, these permanent metal devices may impair coronary imaging, predispose patients to late stent thrombosis, prevent positive remodeling and hinder revascularization. A study presented today at the American College of Cardiology's Innovation in Intervention: i2Summit assesses the safety and performance of a bioabsorbable stent that, if effective, could eliminate several of the problems associated with metallic stents.
Similar news · Read more »
- Researchers begin randomized double-blind trial of airway bypass treatment for emphysema
05-17-2007 · EurekAlert!
Broncus Technologies Inc., today announced the start of its EASE (Exhale Airway Stents for Emphysema) Trial to explore an investigational procedure that may offer a new, minimally-invasive treatment option for millions of emphysema sufferers. The study focuses on a procedure called airway bypass that uses drug-eluting stents to reinforce new pathways in the lung for trapped air to escape. This in turn, may relieve severe emphysema symptoms such as shortness of breath.
Similar news · Read more »
- Stanford analysis shows little difference in risk rates for angioplasty, bypass procedures
10-15-2007 · EurekAlert!
Patients with heart disease who undergo coronary angioplasty have an equivalent risk of death and heart attack as patients who undergo coronary bypass surgery, according to Stanford University School of Medicine researchers. The researchers also found that the survival rates for bypass surgery and angioplasty were similar for patients with diabetes, refuting previous reports that angioplasty was associated with a significantly higher risk of death among diabetic patients.
Similar news · Read more »
- Bare-metal stents are better for some heart patients
05-11-2007 · EurekAlert!
While drug-eluting stents are effective in keeping open diseased heart arteries, they should not be used for patients who need to have noncardiac surgery a short time after an interventional heart procedure. A presentation at the Society for Cardiovascular Angiography and Interventions in Orlando by cardiologists at Jefferson Medical College indicates that for these patients, bare metal stents provide a safer choice.
Similar news · Read more »
- Drug used in coronary artery bypass graft surgery may increase risk of death
02-06-2007 · EurekAlert!
Aprotinin, a drug used for limiting blood loss in patients undergoing cardiac surgery, is associated with an increased risk of death during five years following the surgery, according to a new study in the Feb. 7 issue of JAMA.
Similar news · Read more »
